Escherichia coli ST8196 is a novel, locally evolved, and extensively drug resistant pathogenic lineage within the ST131 clonal complex.

Hastak, P; Fourment, M; Darling, AE; Gottlieb, T; Cheong, E; Merlino, J; Myers, GSA; Djordjevic, SP; Chowdhury, PR

Escherichia coli ST8196 is a novel, locally evolved, and extensively drug resistant pathogenic lineage within the ST131 clonal complex.

Hastak, P Fourment, M Darling, AE Gottlieb, T Cheong, E Merlino, J Myers, GSA Djordjevic, SP Chowdhury, PR

Permalink

Publisher:: Informa UK Limited
Publication Type:: Journal Article
Citation:: Emerging microbes & infections, 2020, pp. 1-35
Issue Date:: 2020-07-20

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted versionAdobe PDF (3.51 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Hastak, P
dc.contributor.author	Fourment, M
dc.contributor.author	Darling, AE
dc.contributor.author	Gottlieb, T
dc.contributor.author	Cheong, E
dc.contributor.author	Merlino, J
dc.contributor.author	Myers, GSA
dc.contributor.author	Djordjevic, SP
dc.contributor.author	Chowdhury, PR
dc.date.accessioned	2020-08-12T06:07:41Z
dc.date.available	2020-08-12T06:07:41Z
dc.date.issued	2020-07-20
dc.identifier.citation	Emerging microbes & infections, 2020, pp. 1-35
dc.identifier.issn	2222-1751
dc.identifier.issn	2222-1751
dc.identifier.uri	http://hdl.handle.net/10453/142066
dc.description.abstract	The H30Rx subclade of Escherichia coli ST131 is a clinically important, globally dispersed extra-pathogenic lineage that typically displays resistance to fluoroquinolones and extended spectrum ß-lactams. Here we describe isolates EC233 and EC234, both variants of ST131-H30Rx with a novel sequence type (ST) 8196, from unrelated patients presenting with bacteraemia at Concord Repatriation Hospital in Sydney in 2014. EC233 and EC234 are phylogroup B2, serotype O25:H4A, resistant to ampicillin, amoxicillin, cefoxitin, ceftazidime, ceftriaxone, ciprofloxacin, norfloxacin and gentamicin and are likely clonal. Both isolates carry an IncFII_2 plasmid similar to pSPRC_Ec234-FII (85,199 bp characterised in EC234), two small plasmids and a novel IncI1 plasmid similar to pSPRC_Ec234-I (92,955 bp characterised in EC234). Apart from a chromosomally located bla CTX-M-15 module, the resistance genes are flanked by IS26 and form a complex resistance locus (CRL) on pSPRC_Ec234-FII. SNP-based phylogenetic analysis of the core genome of all ST representatives within the ST131 clonal complex places both isolates in a small subclade with 3 other clinical Australian ST131-H30Rx clade C isolates. MrBayes phylogeny analysis of ST8196 using a global collection of ST131 genomes indicated EC233 and EC234 share a most recent common ancestor with EC70, a MDR ST131-H30Rx clone, isolated from the same Sydney hospital in 2013. Our study identified genomic hallmarks that define the ST131-H30Rx subclade in both the ST8196 isolates and highlights the requirement for unbiased genomic surveillance approaches to identify and track novel high-risk MDR E. coli pathogens that impact healthcare facilities.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Informa UK Limited
dc.relation.ispartof	Emerging microbes & infections
dc.relation.isbasedon	10.1080/22221751.2020.1797541
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0605 Microbiology
dc.title	Escherichia coli ST8196 is a novel, locally evolved, and extensively drug resistant pathogenic lineage within the ST131 clonal complex.
dc.type	Journal Article
utslib.location.activity	United States
utslib.for	0605 Microbiology
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - ithree - Institute of Infection, Immunity and Innovation
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	open_access	*
dc.date.updated	2020-08-12T06:07:20Z
pubs.publication-status	Published

Abstract:

The H30Rx subclade of Escherichia coli ST131 is a clinically important, globally dispersed extra-pathogenic lineage that typically displays resistance to fluoroquinolones and extended spectrum ß-lactams. Here we describe isolates EC233 and EC234, both variants of ST131-H30Rx with a novel sequence type (ST) 8196, from unrelated patients presenting with bacteraemia at Concord Repatriation Hospital in Sydney in 2014. EC233 and EC234 are phylogroup B2, serotype O25:H4A, resistant to ampicillin, amoxicillin, cefoxitin, ceftazidime, ceftriaxone, ciprofloxacin, norfloxacin and gentamicin and are likely clonal. Both isolates carry an IncFII_2 plasmid similar to pSPRC_Ec234-FII (85,199 bp characterised in EC234), two small plasmids and a novel IncI1 plasmid similar to pSPRC_Ec234-I (92,955 bp characterised in EC234). Apart from a chromosomally located bla CTX-M-15 module, the resistance genes are flanked by IS26 and form a complex resistance locus (CRL) on pSPRC_Ec234-FII. SNP-based phylogenetic analysis of the core genome of all ST representatives within the ST131 clonal complex places both isolates in a small subclade with 3 other clinical Australian ST131-H30Rx clade C isolates. MrBayes phylogeny analysis of ST8196 using a global collection of ST131 genomes indicated EC233 and EC234 share a most recent common ancestor with EC70, a MDR ST131-H30Rx clone, isolated from the same Sydney hospital in 2013. Our study identified genomic hallmarks that define the ST131-H30Rx subclade in both the ST8196 isolates and highlights the requirement for unbiased genomic surveillance approaches to identify and track novel high-risk MDR E. coli pathogens that impact healthcare facilities.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/142066